ARQ761 + PARP Inhibitor in Refractory Solid Tumors

Stopped Project Never Initiated - no human subjects were enrolled and no data regarding humans was collected or studied

Conditions

• Lymphoma

Interventions

• DRUG: ARQ761, Olaparib

Sponsor

University of Texas Southwestern Medical Center